Aseptic processing demands reliable, robust, and validated analytical methods to ensure sterility, safety, and quality, ...

Wood product manufacturers must develop a company-wide attitude that errors are not acceptable if they are going to cost-efficiently produce products of a quality that will compete in today's global ...

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

Wegovy tablets are expected to be available in early January 2026. The Food and Drug Administration (FDA) has approved Wegovy ® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) ...

For organizations that conduct background checks, 2025 was not just about tracking new laws. It was about rethinking how ...

Weight loss pills have been around for decades, but many were deemed unsafe by the FDA. Learn more about today’s ...

The FDA has approved once-daily oral semaglutide 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. The new indication is “to reduce excess body weight and ...

Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETX-19477, the company’s internally ...

Medical errors remain one of the leading causes of death worldwide, rivaling heart disease and cancer. Yet while medicine has ...

Novo Nordisk ( (NVO)) has issued an update. On 22 December 2025, Novo Nordisk reported that the US Food and Drug Administration approved its once‑daily Wegovy pill (oral semaglutide 25 mg), the first ...

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.